Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroblastoma 5 Prostatic Neoplasms 3 Skin Neoplasms 2 Precancerous Conditions 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Osteosarcoma 1 Non-melanoma Skin Cancer 1 Neoplasms 1 Medulloblastoma 1 Keratosis, Actinic 1 Gastritis, Atrophic 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Basal Cell 1 Adenomatous Polyps 1 Adenomatous Polyposis Coli 1

Interventions

Gemcitabine 53 Bevacizumab 52 Cyclophosphamide 49 Docetaxel 42 Carboplatin 40 pembrolizumab 37 Paclitaxel 36 Fluorouracil 36 Cisplatin 35 Radiotherapy 31 Oxaliplatin 31 Capecitabine 29 Irinotecan 28 Dexamethasone 27 Leucovorin 25 Cetuximab 25 Nivolumab 24 Doxorubicin 22 Drug Therapy 21 Erlotinib Hydrochloride 20 Pemetrexed 19 durvalumab 18 trametinib 17 fludarabine 16 atezolizumab 16 Trastuzumab 16 Sunitinib 16 Rituximab 16 Prednisone 16 Sorafenib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × Eflornithine × Clear all

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡